Richard DiMarchi

Q: What Schools Are Affiliated With Richard DiMarchi

Richard DiMarchi is affiliated with the following schools: East Carolina University, Indiana University, Florida Atlantic University

Richard DiMarchi's AcademicInfluence.com Rankings

Richard DiMarchi

Chemistry

#5201

World Rank

#6343

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Why Is Richard DiMarchi Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Richard D. DiMarchi is the current chairman in biomolecular sciences and professor of chemistry at Indiana University. He is most notable for his work as a former vice president at Eli Lilly and Company.

(See a Problem?)

Richard DiMarchi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Crystal structure of the obese protein Ieptin-E100 (1997) (707)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. (2009) (489)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans (2013) (450)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents (2014) (439)
Glucagon-like peptide 1 (GLP-1) (2019) (438)
Protection of cattle against foot-and-mouth disease by a synthetic peptide. (1986) (394)
Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. (1997) (362)
Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment (1997) (303)
Leptin: structure, function and biology. (2005) (296)
The metabolic actions of glucagon revisited (2010) (287)
Effects of obestatin on energy balance and growth hormone secretion in rodents. (2007) (279)
Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism (2009) (248)
Targeted estrogen delivery reverses the metabolic syndrome (2012) (247)
Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. (1997) (219)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. (2017) (211)
Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling (2012) (202)
The New Biology and Pharmacology of Glucagon. (2017) (202)
Altering the association properties of insulin by amino acid replacement. (1992) (199)
Pursuit of a perfect insulin (2016) (185)
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions (2013) (184)
Optimized clinical performance of growth hormone with an expanded genetic code (2011) (184)
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. (2016) (176)
Insulin structure and function. (2007) (159)
Anti-obesity drug discovery: advances and challenges (2021) (159)
Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity (2009) (151)
Synthesis and conformational analysis of a cyclic peptide obtained via i to i+4 intramolecular side-chain to side-chain azide-alkyne 1,3-dipolar cycloaddition. (2008) (150)
Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor (1997) (141)
FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents (2012) (139)
Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease (2016) (137)
Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21 (2012) (132)
A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. (1991) (127)
Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. (1997) (124)
GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet (2014) (118)
Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. (1997) (118)
Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis. (2006) (117)
Reappraisal of GIP Pharmacology for Metabolic Diseases. (2016) (116)
IGF-I–Stimulated Glucose Transport in Human Skeletal Muscle and IGF-I Resistance in Obesity and NIDDM (1990) (112)
GLP-1/glucagon receptor co-agonism for treatment of obesity (2017) (111)
Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells. (2013) (102)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism (2018) (100)
Both Acyl and Des-Acyl Ghrelin Regulate Adiposity and Glucose Metabolism via Central Nervous System Ghrelin Receptors (2013) (98)
Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents (2012) (98)
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes (2018) (97)
Melanocortin signaling in the CNS directly regulates circulating cholesterol (2010) (95)
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists (2018) (95)
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties (2015) (93)
Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus. (1990) (93)
Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice. (2014) (88)
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases (2018) (86)
The rapid identification of HIV protease inhibitors through the synthesis and screening of defined peptide mixtures. (1991) (82)
Fibroblast growth factor 21 night watch: advances and uncertainties in the field (2017) (80)
Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. (1994) (77)
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice (2017) (74)
Peptide lipidation stabilizes structure to enhance biological function. (2013) (72)
Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) (71)
MHC class II restricted recognition of FMDV peptides by bovine T cells. (1991) (70)
Glucagon regulation of energy metabolism (2010) (70)
High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. (1991) (69)
Weak acid-catalyzed pyrrolidone carboxylic acid formation from glutamine during solid phase peptide synthesis. Minimization by rapid coupling. (2009) (68)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling (2020) (67)
Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. (2017) (64)
Metabolic Effects of IGF-I in Diabetic Rats (1991) (63)
Fibroblast activation protein (FAP) as a novel metabolic target (2016) (59)
The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms (2013) (58)
A new quorum‐sensing system (TprA/PhrA) for Streptococcus pneumoniae D39 that regulates a lantibiotic biosynthesis gene cluster (2015) (56)
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety (2019) (56)
pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity (2007) (55)
GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight (2016) (55)
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 in people with type 2 diabetes mellitus (2017) (54)
Unnatural amino acid substitution as a probe of the allosteric coupling pathway in a mycobacterial Cu(I) sensor. (2009) (54)
Optimization of the Native Glucagon Sequence for Medicinal Purposes (2010) (54)
Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. (1991) (54)
Viral insulin-like peptides activate human insulin and IGF-1 receptor signaling: A paradigm shift for host–microbe interactions (2018) (50)
Mechanism of IGF-I-Stimulated Glucose Transport in Human Adipocytes: Demonstration of Specific IGF-I Receptors Not Involved in Stimulation of Glucose Transport (1989) (47)
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 (2018) (46)
A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. (2011) (41)
Synthesis of a Fast-Acting Insulin Based on Structural Homology with Insulin-Like Growth Factor I, (1992) (41)
Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus (1990) (40)
Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice (2015) (39)
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 after single subcutaneous administration in healthy subjects (2017) (38)
Effect of insulin and insulin-like growth factors I and II on phosphatidylinositol and phosphatidylinositol 4,5-bisphosphate breakdown in liver from humans with and without type II diabetes. (1989) (37)
Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents (2018) (37)
Chemical synthesis of insulin analogs through a novel precursor. (2014) (37)
GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice (2014) (36)
GLP-1R Responsiveness Predicts Individual Gastric Bypass Efficacy on Glucose Tolerance in Rats (2014) (35)
Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis (2015) (34)
Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity (2012) (33)
Chemical synthesis of peptides within the insulin superfamily (2016) (32)
Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment (2017) (31)
Allosteric inhibition of a zinc-sensing transcriptional repressor: insights into the arsenic repressor (ArsR) family. (2013) (31)
Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs (2018) (30)
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology (2018) (30)
Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury (2017) (30)
A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia☆ (2014) (30)
Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway (2019) (29)
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists (2021) (28)
Immunization against foot-and-mouth disease with synthetic peptides representing the C-terminal region of VP1. (1988) (28)
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates (2019) (27)
Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. (1991) (27)
Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity (2018) (27)
Current and Emerging Treatment Options in Diabetes Care. (2016) (25)
Synthesis of Four-Disulfide Insulin Analogs via Sequential Disulfide Bond Formation. (2017) (25)
Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury (2020) (24)
IGF-II receptors and IGF-II-stimulated glucose transport in human fat cells. (1990) (24)
Basal activity profiles of NPH and [Nɛ-palmitoyl Lys (B29)] human insulins in subjects with IDDM (1998) (24)
Charge inversion at position 68 of the glucagon and glucagon‐like peptide‐1 receptors supports selectivity in hormone action (2011) (24)
In Vitro and in Vivo Evaluation of Native Glucagon and Glucagon Analog (MAR-D28) during Aging: Lack of Cytotoxicity and Preservation of Hyperglycemic Effect (2010) (23)
Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes (2017) (23)
Maturation of functional antibody affinity in animals immunised with synthetic foot-and-mouth disease virus. (1992) (22)
Insulin-like growth factor-I in non-insulin-dependent diabetic monkeys: basal plasma concentrations and metabolic effects of exogenously administered biosynthetic hormone. (1991) (21)
GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats (2013) (20)
Infusion of human insulin-like growth factor I (IGF-I) into malnourished rats reduces hepatic IGF-I mRNA abundance. (1989) (20)
Zn-regulated GTPase metalloprotein activator 1 modulates vertebrate zinc homeostasis (2022) (19)
Photolabile multi-detachable p-alkoxybenzyl alcohol resin supports for peptide fragment or semi-synthesis. (2009) (19)
CNS-targeting pharmacological interventions for the metabolic syndrome. (2019) (19)
Biomimetic Synthesis of Insulin Enabled by Oxime Ligation and Traceless "C-Peptide" Chemical Excision. (2017) (19)
Bioavailability and Bioeffectiveness of Subcutaneous Human Insulin and Two of its Analogs—LysB28ProB29-Human Insulin and AspB10LysB28ProB29-Human Insulin—Assessed in a Conscious Pig Model (1997) (18)
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes (2022) (18)
Acylation type determines ghrelin's effects on energy homeostasis in rodents. (2012) (18)
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) (18)
Optimization of peptide-based polyagonists for treatment of diabetes and obesity. (2017) (17)
Ghrelin-induced hypothermia: A physiological basis but no clinical risk (2011) (16)
Insights into incretin-based therapies for treatment of diabetic dyslipidemia. (2020) (16)
Synthetic Advances in Insulin-like Peptides Enable Novel Bioactivity. (2017) (16)
Combinatorial libraries of synthetic peptides as a model for shotgun proteomics. (2010) (16)
Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. (2007) (16)
Functional association of the N‐terminal residues with the central region in glucagon‐related peptides (2011) (16)
Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. (2017) (15)
Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia (2018) (15)
Current and Emerging Treatment Options (2015) (14)
Discovery of a β-MSH-derived MC-4R selective agonist (2005) (14)
Complete amino acid sequence of the major component myoglobin of finback whale (Balaenoptera physalus). (1978) (14)
GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice (2019) (13)
Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. (2010) (13)
Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury (2019) (13)
Cross-reactive and serotype-specific antibodies against foot-and-mouth disease virus generated by different regions of the same synthetic peptide (1992) (13)
An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. (2018) (13)
Stimulation of glucose uptake by insulin-like growth factor II in human muscle is not mediated by the insulin-like growth factor II/mannose 6-phosphate receptor. (1994) (13)
Synthetic Route to Human Relaxin-2 via Iodine-Free Sequential Disulfide Bond Formation. (2016) (13)
Synthesis of relaxin‐2 and insulin‐like peptide 5 enabled by novel tethering and traceless chemical excision (2017) (12)
A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction. (2013) (12)
The interaction of proinsulin with the insulin-like growth factor-I receptor in human liver, muscle, and adipose tissue. (1991) (12)
Structural significance of the amino-terminal residues of sperm whale myoglobin. (1980) (11)
Chemical Synthesis of Human Insulin-Like Peptide-6. (2016) (11)
Characterization of the reaction of methyl acetimidate with sperm whale myoglobin. (1978) (11)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Design and synthesis of a multi-detachable benzhydrylamine-resin for solid phase peptide synthesis (1981) (11)
Glucagon receptor signaling regulates weight loss via central KLB receptor complexes (2021) (11)
Human Insulin Analogs with Rapid Onset and Short Duration of Action (1992) (10)
Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold. (2005) (10)
Solid phase synthesis of the protected 43-55 tridecapeptide of the heavy chain of myeloma immunoglobin M603, employing cyclohexyl ester protection for glutamic acid. (2009) (10)
A Brain-Melanocortin-Vagus Axis Mediates Adipose Tissue Expansion Independently of Energy Intake (2019) (10)
Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists. (2007) (10)
The Structural Refinement of Glucagon for Therapeutic Use. (2019) (10)
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. (2021) (10)
The islet-expressed Lhx1 transcription factor interacts with Islet-1 and contributes to glucose homeostasis. (2019) (9)
A disulfide-scan of insulin by [3+1] methodology exhibits site-specific influence on bioactivity. (2019) (9)
Pyridyl-alanine as a Hydrophilic, Aromatic Element in Peptide Structural Optimization. (2016) (9)
MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice (2020) (9)
Analysis of immune responses in the sheep to synthetic peptides of foot-and-mouth disease virus using ovine polyclonal and monoclonal antibodies. (1990) (9)
Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. (1998) (8)
Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles (2005) (8)
Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice (2019) (8)
Myoglobin semisynthesis: removal of the NH2-terminal valine of sperm whale myoglobin and its subsequent reincorporation. (1979) (8)
Synthesis of the protected tridecapeptide (56-68) of the VH domain of mouse myeloma immunoglobulin M603 and its reattachment to resin supports. (2009) (8)
Stereochemical inversion as a route to improved biophysical properties of therapeutic peptides exemplified by glucagon (2019) (8)
Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression. (2019) (8)
Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice (2020) (8)
Native Design of Soluble, Aggregation-Resistant Bioactive Peptides: Chemical Evolution of Human Glucagon. (2016) (7)
“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease (2018) (7)
Synthesis of disulfide-rich heterodimeric peptides through an auxiliary N, N-crosslink (2018) (7)
Addition of Sialic Acid to Insulin Confers Superior Physical Properties and Bioequivalence. (2020) (7)
Smarter Modeling to Enable a Smarter Insulin (2020) (6)
High-Yield Synthesis of Human Insulin-Like Peptide 5 Employing a Nonconventional Strategy. (2018) (6)
Emerging Poly‐Agonists for Obesity and Type 2 Diabetes (2017) (6)
Discovery of a beta-MSH-derived MC-4R selective agonist. (2005) (6)
Altering the Self-Association and Stability of Insulin by Amino Acid Replacement (1993) (5)
HEART RATE, SHEAR STRESS, ATHEROGENESIS AND PLAQUE RUPTURE : IS THERE A LINK ? (1998) (5)
A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor (2021) (5)
Investigation of the Feasibility of an Amide-based Prodrug Under Physiological Conditions (2008) (5)
Side chain-to-side chain cyclization by intramolecular click reaction--building blocks, solid phase synthesis and conformational characterization. (2009) (4)
Synthesis and Characterization of the R27S Genetic Variant of Insulin‐like Peptide 5 (2018) (4)
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice (2022) (4)
1 ! 1 ! A new quorum sensing system ( TprA / PhrA ) for Streptococcus pneumoniae D 39 that 2 ! regulates a lantibiotic biosynthesis gene cluster 3 ! 4 ! 5 ! (2015) (4)
Identification of a second Klotho interaction site in the C terminus of FGF23. (2021) (4)
Sexual dimorphic porcine pituitary response to growth hormone-releasing hormone. (1990) (4)
The orphan receptor GPR83 regulates systemic energy metabolism via ghrelin-dependent and -independent mechanisms (2013) (3)
Drugging the undruggable. (2005) (3)
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21. (2020) (3)
Break on through to the other 1. (2014) (3)
Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker. (2013) (3)
Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via CNS ghrelin receptors. Short Title: CNS ghrelin receptor regulation of metabolism (2013) (3)
Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity (2018) (3)
Discovery and Structural Optimization of High Affinity Co- Agonists at the Glucagon and GLP-1 Receptors (2006) (3)
Synthesis and Biological Assessment of Insulin-Like Analogs with Differential Activity at the Insulin and IGF-1 Receptors (2006) (2)
Chemical Potentiation of Growth Hormone Releasing Hormone Analogs (1992) (2)
Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes (2022) (2)
Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) (2)
Modified-live infectious bovine rhinotracheitis virus (IBRV) vaccine expressing foot-and-mouth disease virus (FMDV) capsid protein epitopes on surface of hybrid virus particles. (1991) (2)
Modulation of T-cell reactivity to synthetic peptide analogues of foot-and-mouth disease virus in sheep by amino acid substitutions. (1992) (2)
Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation (2022) (2)
Gut Peptide Agonism in the Treatment of Obesity and Diabetes. (2019) (2)
Investigation of the Feasibily of an Amide-based Prodrug Under Physiological Conditions (2008) (2)
Icodec Advances the Prospect of Once-Weekly Insulin Injection. (2021) (2)
Three‐chain insulin analogs demonstrate the importance of insulin secondary structure to bioactivity (2015) (2)
Peptide Model of the Mutant Proinsulin Syndrome. II. Nascent Structure and Biological Implications (2022) (2)
Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist (2022) (2)
Erratum: Basal activity profiles of NPH and [N(ε)-palmitoyl Lys (B29)] human insulins in subjects with IDDM (Rapid communication) (Diabetologia (1998) 41 (116-120)) (1998) (2)
Once Blind, Now We See GLP-1 Molecular Action. (2017) (2)
Author Correction: Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) (1)
Recent advances in the chemical synthesis of insulin and related peptides. (2020) (1)
Structure-function relationship in protection against foot and mouth disease (FMD) by a synthetic peptide (1988) (1)
A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs (2021) (1)
Novel Combinatorial Therapies Involving Leptin: Opportunities for Mechanistic Advances and Therapeutic Translation in Human Diseases (2015) (1)
Glucagon Regulates Energy Balance via FGF-21 Signaling in the Brain (2018) (1)
Exploration and Elaboration of Reported Insulin Superagonism through Site-Selective Replacement at TyrB26 (2006) (1)
A-C-B Human Proinsulin: A Novel Insulin Agonist and Intermediate in the Synthesis of Human Insulin, (1992) (1)
Max Bergmann award lecture:Macromolecular medicinal chemistry as applied to metabolic diseases (2018) (1)
Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome (2022) (1)
230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice (2022) (1)
1725-P: Viral Insulins as Agonists and Antagonists on Insulin/IGF-1 Receptors (2020) (1)
Crystallization and preliminary x-ray analysis of anti-obesity peptide hormone oxyntomodulin. (2008) (1)
Insulin, IGFs and Growth Hormone: From Basic Research to Novel Clinical Applications: Interlaken, October 1993 (1994) (0)
Glucagon Regulates Energy Balance via FGF21 Signaling in the Brain (2020) (0)
Glucagon-Receptor Signaling Regulates Mitochondrial Bioenergetics via Hepatic Farnesol X Receptor (2018) (0)
Crystal structure of glucagon analog with 4-bromo-phenylalanine substitutions at position 6 and 22 in space group I41 at 1.65 A resolution (2020) (0)
A process for the purification of the proinsulin-like materials (1986) (0)
Sulfoxide waste reduction process methionine (1988) (0)
A method of reducing methionine sulfoxide groups in peptides and proteins (1988) (0)
Analogs of insulinotropic peptides glucagon type, compositions and methods of use. (1995) (0)
IGF-1 Superagonisten (1996) (0)
Glukagonintapaisia tropical insulin peptide analogs, compositions and methods of use (1995) (0)
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight in obese mice (2022) (0)
Hypothalamic Glucagon Receptors Regulate Feeding in Mice (2021) (0)
GLP-1 compounds bound to polyethylene glycol (2004) (0)
Single chain insulin with high bioactivity (1997) (0)
Crystal structure of glucagon analog with mono-stereoinversion at position 21 (D-Asp21) in space group I41 at 1.18 A resolution (2020) (0)
Homeostatic and hedonic mechanisms underlying CNS-regulated metabolism (2019) (0)
Use of analogs and derivatives of GLP-1 administered peripherally for the regulation of obesity. (1997) (0)
Crystal structure of glucagon analog with selenomethionine substitutions at position 1 and 27 in space group I41 at 1.42 A resolution (2020) (0)
American peptides Symposium Breaking Away: Indiana University Bloomington June 7 - 12 2009 (2009) (0)
Disulfide as a Constraint to Build Super Potent and Selective Melanocortin-4 Receptor (MC4R) Agonists (2006) (0)
Selective chemical remove of a protein amino terminal residue (1986) (0)
1870-P: Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression (2019) (0)
936-P: Plasma Proteomic Profiling Delineates Treatment Efficacy of a GLP-1/GIP Coagonist in Female and Male Mice (2020) (0)
Synthesis and Biological Assessment of Sulfonic Acid-Based Glucagon Antagonists (2006) (0)
A process for inhibiting carbamylation of peptides during treatment of said peptides (1985) (0)
A Monomeric Peptide Triagonist for the Treatment of Obesity and Diabetes (2015) (0)
GLP-1 based multi-agonists-induced signaling includes profound TRP channel involvement in insulin secretion (2017) (0)
pI-shifted Basal Insulin Analogs with High Selectivity for Insulin vs IGF-1 Receptor (2006) (0)
17β-Estradiol-gekoppeltes GLP-1 verhindert den Betazelluntergang in einem Mausmodell für Typ-2-Diabetes (2013) (0)
Author response: MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice (2020) (0)
conjungados-antagonist and compositions GIP agonist glucagon for the treatment of metabolic disorders and obesity (2011) (0)
GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice (2021) (0)
Crystal structure of glucagon analog fully composed of D-amino acids with 4-bromo-D-phenylalanine substitutions at position 6 and 22 in space group I41 at 1.1 A resolution (2020) (0)
Glucagon-like peptide 1 (GLP-1). (2019) (0)
Peptides glucagon superfamily receptor activity showing nuclear hormone (2011) (0)
Statistical and Operational Issues Arising in an Interim Analysis When the Study Will Continue (1999) (0)
Advances in the treatment of metabolic diseases (2021) (0)
Synthesis and activity of proteolysis-resistant GLP-1 analogs (2002) (0)
Author Correction: Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) (0)
Process for the preparation of peptides and means for use in the method (1986) (0)
Chemical synthesis of human epidermal growth factor (EGF) and human type α transforming growth factor (TGFα) (1988) (0)
Glucagon-like insulinotropic peptide analog and composition (1995) (0)
A Novel Approach to Resin-based Cysteine Alkylation (2006) (0)
Cross-Reactive andSerotype-Specifi c Antibodies against Foot-and-Mouth Disease VirusGenerated byDifferent Regions oftheSameSynthetic Peptide (1992) (0)
Structurally Constrained Insulin Analogs by Directed Stepwise Crosslinking. (2019) (0)
Novel Oral Agents: The Search for Transformational Medicines (2012) (0)
197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation (2022) (0)
OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice (2019) (0)
Modified human or plasmapolypeptid fc scaffolds and their uses (2007) (0)
Efficacy of a Glucagon-Like Peptide-1 and Estrogen Dual Agonist in Pancreatic Islets Protection and Pre-Clinical Models of Insulin-Deficient Diabetes (2022) (0)
Crystal structure of glucagon analog fully composed of D-amino acids in space group I41 at 1.1 A resolution (2020) (0)
New advances in insulin treatment of diabetes: overcoming barriers. (1997) (0)
FGF21: starvation hormone to a clinical drug? (2015) (0)
Discovery and Optimization of β-MSH Derived Melanocortin-4 Selective Agonists (2006) (0)
Process for the preparation of therapeutically useful insulin analogues (1990) (0)
DESIGN AND SYNTHESIS OF A MULTIDETACHABLE BENZHYDRYLAMINE RESIN FOR SOLID PHASE PEPTIDE SYNTHESIS (1981) (0)
336-OR: Mandarin Fish Ranavirus Viral Insulin/IGF-Like Peptide Inhibits Human IGF-1 Receptor (2021) (0)
A method of reducing residues methionine sulfoxide (1988) (0)
Analog of growth liberating factor. (1984) (0)
Optimization of the C-terminal Sequence in Glucagon to Maximize Receptor Affinity (2006) (0)
Recently published papers in the field of molecular (2005) (0)
Glucagon analogs that exhibit greater solubility in physiological pH buffers (2008) (0)
Glucagon analogs that show solubility and stability physiological (2006) (0)
Crystal structure of glucagon analog with mono-stereoinversion at position 23 (D-Val23) in space group I41 at 1.44 A resolution (2020) (0)
GLP-1 directed delivery of dexamethasone ameliorates hypothalamic inflammation and reverses diet-induced obesity (2016) (0)
Glucagon analogs that show solubility and physiological stability (2006) (0)
based mixed GIP for the treatment of metabolic disorders and obesity agonists (2009) (0)
Anti-obesity drug discovery: advances and challenges (2021) (0)
Analogs releasing factor growth hormone. (1991) (0)
Solid phase synthesis of the protected 43-55 tridecapeptide of the heavy chain of myeloma immunoglobin M 603 , employing cyclohexyl ester protection for glu tamic acid (2008) (0)
1965-P: Glucagon Receptor Agonism Stimulates Body Weight Loss in Antibiotic Treatment in Obese Mice (2019) (0)
SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice (2020) (0)
Acb proinsulin, method of preparation and use and intermediates in the production of insulin. (1992) (0)
Glp-1 amide (2001) (0)
Crystal structure of native glucagon in space group P213 at 1.99 A resolution (2020) (0)
ABC-proinsulin, method of making and using the same, and intermediates in the insulin-producing (1992) (0)
A-c-b proinsulin, its production, method for using it and intermediate in insulin production (1992) (0)
Protection induced by synthetic peptides corresponding to three serotypes in foot and mouth disease virus. (1989) (0)
Compounds exhibiting antagonistic activity of glucagon and GLP-1 agonist (2008) (0)
Crystal structure of glucagon analog composed of D-amino acids with mono-stereoinversion at position 23 (L-Val23) in space group I41 at 1.33 A resolution (2020) (0)
Hepatic TORC2 Signaling Facilitates Acute Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice. (2022) (0)
foot-and-mouth disease virus. peptides corresponding to three serotypes of Heterotypic protection induced by synthetic (2013) (0)
ACB-proinsulin, methods for its preparation and use, and intermediates in the insulin production (1992) (0)
Crystal structure of native glucagon in space group I41 at 1.1 A resolution (2020) (0)

This paper list is powered by the following services:

Other Resources About Richard DiMarchi

en.wikipedia.org

What Schools Are Affiliated With Richard DiMarchi?

Richard DiMarchi is affiliated with the following schools: